Labcyte garners $21M in third venture round

Labcyte has wrapped its third round of venture capital with $21 million in new funding. The round was led by Cross Atlantic Partners and included Hambrecht & Quist Capital Management and the Bay Area Equity Fund, a fund managed by JPMorgan, as new investors. Their money will be employed to expand Labcyte's fluid handling business, which is sold to researchers who work with assay plates.

- read this press release for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.